Evidence map›Paper›PMID 39064468›Full record

ArticleMedicina (Kaunas, Lithuania)2024

Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.

Kevin Doello, Maria Angeles Chico, Francisco Quiñonero, Raúl Ortiz, Jose Prados, Cristina Mesas, Consolación Melguizo

Abstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Native Ligand-Inspired peptides for c-MET targeted PET probes development.European journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kevin DoelloMedical Oncology Service, Virgen de las Nieves Hospital, 18014 Granada, Spain.
Maria Angeles ChicoInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain.
Francisco QuiñoneroInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100 Granada, Spain.ORCID 0000-0002-9087-8161
Raúl OrtizInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain.
Jose PradosInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100 Granada, Spain.ORCID 0000-0003-4303-7746
Cristina MesasInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain.
Consolación MelguizoInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100 Granada, Spain.ORCID 0000-0003-3990-806X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, HormonalNeuroendocrine TumorsOctreotideReceptors, SomatostatinSomatostatinAgedCell ProliferationFemaleHormonesHumansMaleMiddle AgedTreatment OutcomeAntineoplastic Agents, HormonalHormonesOctreotidepasireotideReceptors, SomatostatinSomatostatincarcinomaneuroendocrine tumorspasireotidesomatostatin receptors

Identifiers

PMID39064468
PMCPMC11279282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.